These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 8434976)

  • 1. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
    Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
    Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
    Chizzolini C; Raschi E; Rezzonico R; Testoni C; Mallone R; Gabrielli A; Facchini A; Del Papa N; Borghi MO; Dayer JM; Meroni PL
    Arthritis Rheum; 2002 Jun; 46(6):1602-13. PubMed ID: 12115192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
    Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion.
    van Lieshout AW; Vonk MC; Bredie SJ; Joosten LB; Netea MG; van Riel PL; Lafyatis R; van den Hoogen FH; Radstake TR
    Scand J Rheumatol; 2009; 38(4):282-90. PubMed ID: 19255934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum interleukin 23 in patients with systemic sclerosis.
    Komura K; Fujimoto M; Hasegawa M; Ogawa F; Hara T; Muroi E; Takehara K; Sato S
    J Rheumatol; 2008 Jan; 35(1):120-5. PubMed ID: 18085738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.
    Jinnin M; Makino T; Kajihara I; Honda N; Makino K; Ogata A; Ihn H
    Br J Dermatol; 2010 Apr; 162(4):751-8. PubMed ID: 19886888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
    Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased interleukin-17 production in patients with systemic sclerosis.
    Kurasawa K; Hirose K; Sano H; Endo H; Shinkai H; Nawata Y; Takabayashi K; Iwamoto I
    Arthritis Rheum; 2000 Nov; 43(11):2455-63. PubMed ID: 11083268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma.
    Ihn H; Sato S; Fujimoto M; Kikuchi K; Takehara K
    Br J Dermatol; 1996 May; 134(5):843-7. PubMed ID: 8736323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis.
    Sato S; Hanakawa H; Hasegawa M; Nagaoka T; Hamaguchi Y; Nishijima C; Komatsu K; Hirata A; Takehara K
    J Rheumatol; 2000 Dec; 27(12):2838-42. PubMed ID: 11128673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features.
    Jimenez-Boj E; Kedersha N; Tohidast-Akrad M; Karlhofer FM; Stummvoll G; Zimmermann C; Ulrich W; Guiducci S; Hoefler E; Aringer M; Schett G; Matucci-Cerinic M; Smolen JS; Steiner G
    Arthritis Rheum; 2008 May; 58(5):1226-36. PubMed ID: 18438838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study.
    Dziankowska-Bartkowiak B; Waszczykowska E; Łuczyńska M; Zalewska A; Sysa-Jedrzejowska A
    Med Sci Monit; 2002 Feb; 8(2):CR108-12. PubMed ID: 11859283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
    Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
    Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered diurnal rhythm of prolactin in systemic sclerosis.
    Hilty C; Brühlmann P; Sprott H; Gay RE; Michel BA; Gay S; Neidhart M
    J Rheumatol; 2000 Sep; 27(9):2160-5. PubMed ID: 10990228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.